In summary, our data demonstrate that combining PI3K inhibitors with EZH1/2 inhibitors may be a promising therapeutic regimen for AML patients, especially for depleting leukemia-initiating cells to reduce the rate of relapse. Here, PIK3CA is linked to acute myeloid leukemia.